-
Corporate Governance
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Enzon Pharmaceuticals Inc.s financial performance into perspective.
Corporate Governance
The members and charters for select committees of Enzon’s Board of Directors.
Committe Composition
To report complaints about Enzon’s accounting, internal accounting controls or auditing matters please call 866-276-2949 at any time of the day or night. You may also submit your complaint by e-mailing enzn@openboard.info or writing to:
Enzon Pharmaceuticals, Inc.
Attn: Chief Compliance Officer
685 Route 202/206
Bridgewater, NJ 08807
You may communicate with Enzon’s Board of Directors by writing to:
Enzon Pharmaceuticals, Inc.
Attn: Chief Compliance Officer
685 Route 202/206
Bridgewater, NJ 08807
= add file to Briefcase
| (ENZN) NASDAQ | |
| Last Trade | 9.850 |
| Change(%) |
0.04
|
| Volume | 651,900 |
| Mar 9, 2010 3:59 PM ET | |
Sign up to receive Enzon Pharmaceuticals Inc. financial information by email.
News
-
Details on upcoming events are not yet available.
click here to be notified of all upcoming events.
-
02-17-2010
Fourth Quarter Earnings Call
-
11-03-2009
Third Quarter Earnings Call
-
08-05-2009
2009 BMO Capital Markets 9th Annual Focus on Healthcare Conference
-
08-04-2009
Second Quarter Earnings Call
-
Really Simple Syndication is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates.
-
03-08-2010
Enzon's Debt is Reduced by $116 Million
--Debt converted into an additional 13.5 million shares--
-
02-24-2010
Enzon Opens Pediatric Study of PEG-SN38
-
02-22-2010
Enzon Board of Directors Appoints Executive Committee
Jeffrey Buchalter Steps Down as CEO of Enzon
-
02-17-2010
Enzon Reports 2009 Results
--Sale of Specialty Pharmaceutical Business brings over $300 million in value--